Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dispersible DTG/ABC/3TC FDC vs Tivicay + Epzicom
NCT02893488Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (5 arms), sponsored by ViiV Healthcare. Primary endpoints: Area under the plasma concentration-time curve from time zero extrapolated to infinite time at 72 hours and Maximum observed plasma concentration at 72 hours. Started Sep 2016; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02893488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893488.